Oncolytics Biotech Stock Today

ONC Stock  CAD 1.45  0.07  5.07%   

Performance

0 of 100

 
Low
 
High
Very Weak

Odds Of Distress

Less than 42

 
100  
 
Zero
Below Average
Oncolytics Biotech is selling at 1.45 as of the 29th of March 2024; that is 5.07 percent increase since the beginning of the trading day. The stock's open price was 1.38. Oncolytics Biotech has about a 42 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Oncolytics Biotech are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 28th of February 2024 and ending today, the 29th of March 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
Category
Healthcare
Classification
Health Care
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada. The company has 75.42 M outstanding shares of which 312.64 K shares are now shorted by private and institutional investors with about 3.97 days to cover all short positions. More on Oncolytics Biotech

Moving together with Oncolytics Stock

  0.67ACB Aurora Cannabis SplitPairCorr

Moving against Oncolytics Stock

  0.88AMZN Amazon CDRPairCorr
  0.88META Meta Platforms CDRPairCorr
  0.85BRK Berkshire Hathaway CDRPairCorr
  0.85WMT Walmart Inc CDRPairCorr
  0.84ME Moneta Gold Earnings Call This WeekPairCorr
  0.79MSFT Microsoft Corp CDRPairCorr
  0.78OGI OrganiGram HoldingsPairCorr

Oncolytics Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Oncolytics Biotech's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Oncolytics Biotech or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CEO PresidentDr MBA
Thematic IdeaIT (View all Themes)
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, IT, Health Care, Biotechnology, Biotechnology, Healthcare, Computing (View all Sectors)
Oncolytics Biotech's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Oncolytics Biotech's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Oncolytics Biotech's financial leverage. It provides some insight into what part of Oncolytics Biotech's total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on Oncolytics Biotech's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Oncolytics Biotech deploys its capital and how much of that capital is borrowed.
Liquidity
Oncolytics Biotech cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company has accumulated 373 K in total debt with debt to equity ratio (D/E) of 0.01, which may suggest the company is not taking enough advantage from borrowing. Oncolytics Biotech has a current ratio of 8.63, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Oncolytics Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Oncolytics Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Oncolytics Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Oncolytics to invest in growth at high rates of return. When we think about Oncolytics Biotech's use of debt, we should always consider it together with cash and equity.

Capital Expenditures

7,600
Oncolytics Biotech (ONC) is traded on Toronto Exchange in Canada and employs 34 people. Oncolytics Biotech is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 109.36 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Oncolytics Biotech's market, we take the total number of its shares issued and multiply it by Oncolytics Biotech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Oncolytics Biotech operates under Biotechnology sector and is part of Health Care industry. The entity has 75.42 M outstanding shares of which 312.64 K shares are now shorted by private and institutional investors with about 3.97 days to cover all short positions. Oncolytics Biotech has accumulated about 11.67 M in cash with (28.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.72.
Check Oncolytics Biotech Probability Of Bankruptcy
Ownership Allocation
Oncolytics Biotech owns a total of 75.42 Million outstanding shares. Oncolytics Biotech holds 6.24 pct. of its outstanding shares held by insiders and 6.98499999999999 pct. owned by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Oncolytics Ownership Details

Oncolytics Stock Price Odds Analysis

Contingent on a normal probability distribution, the odds of Oncolytics Biotech jumping above the current price in 90 days from now is about 67.96%. The Oncolytics Biotech probability density function shows the probability of Oncolytics Biotech stock to fall within a particular range of prices over 90 days. Assuming the 90 days trading horizon Oncolytics Biotech has a beta of 0.8214. This indicates as returns on the market go up, Oncolytics Biotech average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Oncolytics Biotech will be expected to be much smaller as well. Additionally, oncolytics Biotech has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming NYSE Composite.
  Odds Below 1.45HorizonTargetOdds Above 1.45
31.91%90 days
 1.45 
67.96%
Based on a normal probability distribution, the odds of Oncolytics Biotech to move above the current price in 90 days from now is about 67.96 (This Oncolytics Biotech probability density function shows the probability of Oncolytics Stock to fall within a particular range of prices over 90 days) .

Oncolytics Biotech Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Oncolytics Biotech market risk premium is the additional return an investor will receive from holding Oncolytics Biotech long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Oncolytics Biotech. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Oncolytics Biotech's alpha and beta are two of the key measurements used to evaluate Oncolytics Biotech's performance over the market, the standard measures of volatility play an important role as well.

Oncolytics Stock Against Markets

Picking the right benchmark for Oncolytics Biotech stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Oncolytics Biotech stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Oncolytics Biotech is critical whether you are bullish or bearish towards Oncolytics Biotech at a given time. Please also check how Oncolytics Biotech's historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Oncolytics Biotech without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Stocks Directory Now

   

Stocks Directory

Find actively traded stocks across global markets
All  Next Launch Module

Oncolytics Biotech Corporate Directors

Oncolytics Biotech corporate directors refer to members of an Oncolytics Biotech board of directors. The board of directors generally takes responsibility for the Oncolytics Biotech's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Oncolytics Biotech's board members must vote for the resolution. The Oncolytics Biotech board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Ger AmersfoortIndependent DirectorProfile
Mark LievonenDirectorProfile
William RiceIndependent DirectorProfile
Robert SchultzLead Independent DirectorProfile

How to buy Oncolytics Stock?

Before investing in Oncolytics Biotech, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Oncolytics Biotech. To buy Oncolytics Biotech stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Oncolytics Biotech. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Oncolytics Biotech stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Oncolytics Biotech stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Oncolytics Biotech stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Oncolytics Biotech, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Oncolytics Stock please use our How to Invest in Oncolytics Biotech guide.

Already Invested in Oncolytics Biotech?

The danger of trading Oncolytics Biotech is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Oncolytics Biotech is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Oncolytics Biotech. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Oncolytics Biotech is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Oncolytics Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oncolytics Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oncolytics Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oncolytics Biotech Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
To learn how to invest in Oncolytics Stock, please use our How to Invest in Oncolytics Biotech guide.
Note that the Oncolytics Biotech information on this page should be used as a complementary analysis to other Oncolytics Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Oncolytics Stock analysis

When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Stocks Directory
Find actively traded stocks across global markets
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Please note, there is a significant difference between Oncolytics Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncolytics Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncolytics Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.